SCHEMBL4055883

SCHEMBL4055883

CC(=O)CCCOc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.61
KCNA3 P22001 1/20 0.58
MTNR1A P48039 1/20 0.58
MTNR1B P49286 1/20 0.58
HPGD P15428 3/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
HDAC1 Q13547 2/20 0.54
HDAC2 Q92769 2/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
LMNA P02545 1/20 0.54
ALOX15 P16050 1/20 0.54
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
HSD17B10 Q99714 1/20 0.54
PKM P14618 1/20 0.53
RECQL P46063 1/20 0.53
TAAR1 Q96RJ0 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15061644 0.94 HDAC1 (0.62) L3MBTL1KCNA3MTNR1AMTNR1BHDAC1
SCHEMBL10361085 0.92 HDAC1 (0.65) L3MBTL1KCNA3MTNR1AMTNR1BHDAC1
SCHEMBL8278956 0.90 MTNR1A (0.59) L3MBTL1KCNA3MTNR1AMTNR1BMEN1
SCHEMBL8823916 0.88 HDAC1 (0.64) L3MBTL1KCNA3HDAC1HDAC2
SCHEMBL9621829 0.85 L3MBTL1 (0.58) L3MBTL1KCNA3MTNR1AMTNR1BHPGD
SCHEMBL7737575 0.84 HDAC1 (0.69) HDAC1HDAC2
SCHEMBL295889 0.83 PPARA (0.66) KCNA3HPGDHDAC1HDAC2NPC1
SCHEMBL10361230 0.83 KCNA3 (0.62) L3MBTL1KCNA3HPGDMEN1KMT2A
SCHEMBL9851540 0.83 TSHR (0.65) L3MBTL1ALOX15TSHRMAPK1HSD17B10
SCHEMBL7739114 0.83 HDAC1 (0.72) HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104860833-A Purification method of dobutamine hydrochloride Shanghai ziyuan pharmaceutical co ltd 2015-08-26 CN claimed
US-20240024497-A1 METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES CIDARA THERAPEUTICS, INC. 2024-01-25 US disclosed
US-10947271-B2 Antibacterial agents THE UNIVERSITY OF QUEENSLAND (AU) 2021-03-16 US disclosed
WO-2021046549-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. (US) 2021-03-11 WO disclosed
US-9856254-B2 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-01-02 US disclosed
US-20170204138-A1 ANTIBACTERIAL AGENTS THE UNIVERSITY OF QUEENSLAND (AU) 2017-07-20 US disclosed
US-20160280707-A1 ALKOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2016-09-29 US disclosed
US-20160280707-A1 ALKOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2016-09-29 US disclosed
US-9365567-B2 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2016-06-14 US disclosed
US-9365567-B2 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2016-06-14 US disclosed
CN-1930140-A Trisubstituted furans suitable for the preparation of fragrance compositions GIVAUDAN SA (CH) 2007-03-14 CN disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed
EP-0241043-B1 NOVEL DIARYLALKANOIDS HAVING ACTIVITY AS LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1993-09-01 EP disclosed
US-5177259-A Diarylalkanoids having activity as lipoxygenase inhibitors WARNER-LAMBERT COMPANY (US) 1993-01-05 US disclosed
US-5142095-A Treating inflammation, allergies, asthma, cardiovascular disorders, psoriasis WARNER-LAMBERT COMPANY (US) 1992-08-25 US disclosed
US-5077411-A Antiallergens, antiinflammatory agents; cardiovascular disorders, migraines, psoriasis WARNER-LAMBERT CO. (US) 1991-12-31 US disclosed
US-4959503-A Diarylalkanoids having activity as lipoxygenase inhibitors WARNER-LAMBERT COMPANY (US) 1990-09-25 US disclosed
US-4810716-A ANTIINFLAMMATORY, ANTIALLERGY, ANTIISCHEMIC WARNER-LAMBERT COMPANY (US) 1989-03-07 US disclosed
EP-0241043-A2 Novel diarylalkanoids having activity as lipoxygenase inhibitors WARNER-LAMBERT COMPANY (US) 1987-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024497-A1 METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES RNGTT, RNMT, DNPEP L3MBTL1 3063/4885KCNA3 4645/4885MTNR1A 3449/4885
US-20160280707-A1 ALKOXY SUBSTITUTED IMIDAZOQUINOLINES IL2, IFNG, IRF3 L3MBTL1 2127/4885KCNA3 4319/4885MTNR1A 1410/4885
US-20170204138-A1 ANTIBACTERIAL AGENTS VNN1, ASNS, AAAS L3MBTL1 153/4885KCNA3 2030/4885MTNR1A 3206/4885
US-10947271-B2 Antibacterial agents VNN1, ASNS, AAAS L3MBTL1 153/4885KCNA3 2030/4885MTNR1A 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.